FDA https://www.fda.gov and NIH https://www.nih.gov have launched the Critical Path for Rare Neurodegenerative Diseases (CP-RND), a public private partnership aimed at advancing the understanding of neurodegenerative diseases and developing treatments for ALS and other rare neurodegenerative diseases.
The Accelerating Access to Critical Therapies for Amyotrophic Lateral Sclerosis Act signed into law December 23, 2021, requires HHS through FDA and NIH to establish and implement a public-private partnership not later than one year after enactment.
The Critical Path Institute (C-Path) has been selected to convene the partnership. C-Path will bring together experts in rare neurodegenerative diseases, including but not limited to patient communities, advocacy organizations, and private entities. The priorities for the effort will be determined with input from the partners.
The FDA-funded Rare Disease Cures Accelerator-Data and Analytics Platform (RDA-DAP), will bring together scientific data on rare neurodegenerative diseases to characterize neurodegenerative diseases and their history, identify molecular targets for neurodegenerative disease, how to increase efficiency and predictability, and how to increase productivity for clinical development of therapies.